236 related articles for article (PubMed ID: 29285579)
1. R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes.
Kawakami S; Ochiai K; Azakami D; Kato Y; Michishita M; Morimatsu M; Ishiguro-Oonuma T; Onozawa E; Watanabe M; Omi T
Vet Res Commun; 2018 Mar; 42(1):49-56. PubMed ID: 29285579
[TBL] [Abstract][Full Text] [Related]
2. Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation.
Kawakami S; Ochiai K; Kato Y; Michishita M; Hirama H; Obara R; Azakami D; Watanabe M; Omi T
J Vet Med Sci; 2018 Jan; 80(1):85-91. PubMed ID: 29162772
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
Fraser AR; Bacci B; le Chevoir MA; Long SN
J Comp Pathol; 2018 Nov; 165():33-39. PubMed ID: 30502793
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation.
Kaneko MK; Tian W; Takano S; Suzuki H; Sawa Y; Hozumi Y; Goto K; Yamazaki K; Kitanaka C; Kato Y
Biochem Biophys Res Commun; 2011 Mar; 406(4):608-13. PubMed ID: 21352804
[TBL] [Abstract][Full Text] [Related]
5. Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability.
Kawakami S; Michishita M; Sakaue M; Morimatsu M; Uemura M; Kashiwagi N; Maeda M; Machida Y; Azakami D; Egusa AS; Onozawa E; Ishioka K; Watanabe M; Tanaka Y; Omi T; Ochiai K
Oncol Lett; 2020 Dec; 20(6):351. PubMed ID: 33123262
[TBL] [Abstract][Full Text] [Related]
6. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
Bleeker FE; Lamba S; Leenstra S; Troost D; Hulsebos T; Vandertop WP; Frattini M; Molinari F; Knowles M; Cerrato A; Rodolfo M; Scarpa A; Felicioni L; Buttitta F; Malatesta S; Marchetti A; Bardelli A
Hum Mutat; 2009 Jan; 30(1):7-11. PubMed ID: 19117336
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Xu Q; Ahmed AK; Zhu Y; Wang K; Lv S; Li Y; Jiang Y
Biochem Biophys Res Commun; 2018 May; 499(4):882-888. PubMed ID: 29625108
[TBL] [Abstract][Full Text] [Related]
8. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
Loussouarn D; Le Loupp AG; Frenel JS; Leclair F; Von Deimling A; Aumont M; Martin S; Campone M; Denis MG
Int J Oncol; 2012 Jun; 40(6):2058-62. PubMed ID: 22447191
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma.
Lu VM; McDonald KL
CNS Oncol; 2018 Jan; 7(1):41-50. PubMed ID: 29303363
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
[TBL] [Abstract][Full Text] [Related]
11. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Kato Kaneko M; Ogasawara S; Kato Y
Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
[TBL] [Abstract][Full Text] [Related]
13. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
[TBL] [Abstract][Full Text] [Related]
14. IDH1 mutation diminishes aggressive phenotype in glioma stem cells.
Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J
Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585
[TBL] [Abstract][Full Text] [Related]
15. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
Lewandowska MA; Furtak J; Szylberg T; Roszkowski K; Windorbska W; Rytlewska J; Jóźwicki W
Mol Diagn Ther; 2014 Feb; 18(1):45-53. PubMed ID: 23934769
[TBL] [Abstract][Full Text] [Related]
16. Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis.
Tiburcio PDB; Xiao B; Berg S; Asper S; Lyne S; Zhang Y; Zhu X; Yan H; Huang LE
Acta Neuropathol; 2018 Feb; 135(2):285-298. PubMed ID: 29288440
[TBL] [Abstract][Full Text] [Related]
17. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.
Kato Y; Jin G; Kuan CT; McLendon RE; Yan H; Bigner DD
Biochem Biophys Res Commun; 2009 Dec; 390(3):547-51. PubMed ID: 19818334
[TBL] [Abstract][Full Text] [Related]
18. Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance.
Fu Y; Zheng S; Zheng Y; Huang R; An N; Liang A; Hu C
Int J Biochem Cell Biol; 2012 May; 44(5):770-5. PubMed ID: 22309944
[TBL] [Abstract][Full Text] [Related]
19. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
[TBL] [Abstract][Full Text] [Related]
20. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
